Weight Loss and Anticoagulant/Antiplatelet Medications
The 10-pound weight loss over one month is almost certainly due to the reduced caloric intake from eating half a sandwich instead of a whole sandwich for lunch, not from Eliquis or Plavix, as neither medication is associated with weight loss as a side effect. 1
Why the Medications Are Not Responsible
Eliquis (Apixaban)
- The FDA prescribing information for apixaban does not list weight loss as an adverse effect 2
- Apixaban's pharmacokinetics show that body weight affects drug exposure modestly, but the drug does not cause weight changes 2
- Studies in obese patients demonstrate that apixaban does not substantially influence body weight or metabolism 2
Plavix (Clopidogrel)
- The FDA label for Plavix does not include weight loss among its adverse effects or warnings 1
- Clopidogrel's mechanism of action involves platelet inhibition through irreversible P2Y12 receptor binding, which has no metabolic effects that would cause weight loss 1
- Body weight affects clopidogrel's pharmacodynamics (higher body weight patients have lower active metabolite concentrations), but the drug itself does not cause weight changes 3
The Dietary Change Explains the Weight Loss
- Reducing lunch from a whole sandwich to half a sandwich represents a significant caloric deficit of approximately 200-400 calories daily (depending on sandwich type)
- Over one month (30 days), this creates a total deficit of 6,000-12,000 calories
- Since one pound of body weight equals approximately 3,500 calories, this dietary change alone accounts for 1.7-3.4 pounds of weight loss per month from lunch reduction alone
- The 10-pound loss suggests additional unmeasured dietary changes or increased activity may also be occurring 4
Important Clinical Considerations
Body weight changes can affect antiplatelet efficacy, particularly with clopidogrel:
- Higher body weight patients on clopidogrel have lower active metabolite concentrations and reduced platelet inhibition 3
- Weight loss may theoretically improve clopidogrel response, though this is not clinically problematic 5, 3
- European Society of Cardiology guidelines indicate no dose adjustment is needed for clopidogrel unless BMI exceeds 35 with poor metabolizer status 5
For apixaban, weight changes have minimal clinical impact:
- Apixaban does not require dose adjustment based on weight above 120 kg 2
- The modest weight loss described would not necessitate any medication adjustment 2
What to Monitor
- Continue current medications without dose adjustment
- Assess whether the weight loss is intentional and sustainable
- If unintentional weight loss continues beyond dietary explanation, investigate other causes (malignancy, thyroid disease, gastrointestinal pathology)
- Monitor for bleeding complications, as both medications increase bleeding risk, though this is unrelated to the weight change 1, 6